Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026.

Rhea-AI Summary

Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update.

According to Altimmune, the live webcast will be available on the company's Investor Relations website, dial-in registration is required for participants, and a replay will be accessible for up to three months.

Argus Feb 26 session

-2.19% close to close Open Argus

Details

News Market Reaction – ALT

On Feb 26, the day this news came out, ALT closed 2.19% below the previous close.

Data tracked by StockTitan Argus for the Feb 26 session.

Market Context

This announcement sets March 5, 2026 as the next checkpoint, when Altimmune will report Q4 and full-...

Analysis

This announcement sets March 5, 2026 as the next checkpoint, when Altimmune will report Q4 and full-year 2025 results and host a business update call at 8:30 a.m. ET. In light of recent financings, clinical milestones in MASH, and leadership changes, that event may provide added clarity on pemvidutide’s development plans, capital deployment, and strategic priorities. Investors may watch for updates that contextualize prior offerings and regulatory progress.

Key Figures

Earnings date: March 5, 2026 Conference call time: 8:30 a.m. ET Current price: $4.56 +2 more

Earnings date

March 5, 2026

Scheduled release for Q4 and full-year 2025 results

Conference call time

8:30 a.m. ET

Time of earnings and business update call on March 5, 2026

Current price

$4.56

Price before earnings-date announcement

52-week range

$2.90 – $7.73

Low and high over the past 52 weeks

Market cap

$572,308,033

Equity value prior to the earnings-date news

Historical Context

5 past events · Latest: Jan 29

5 events

1. Jan 29

   Offering closing

   24h Move

   +9.8%

   Closed $75M registered direct offering to fund Phase 3 pemvidutide trial.

2. Jan 27

   Offering pricing

   24h Move

   -17.1%

   Priced $75M registered direct offering of common stock and pre-funded warrants.

3. Jan 05

   Regulatory designation

   24h Move

   +16.5%

   Received FDA Breakthrough Therapy Designation for pemvidutide in MASH.

4. Dec 19

   Clinical data update

   24h Move

   -22.8%

   Reported positive 48-week IMPACT Phase 2b pemvidutide MASH trial results.

5. Dec 01

   Leadership change

   24h Move

   -6.3%

   Announced CEO transition and succession plan effective January 1, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
lroth@burnsmc.com

Media Contact:
Real Chemistry
altimmune@realchemistry.com 

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Altimmune (ALT) report Q4 and full year 2025 results and when is the conference call?

Altimmune will report Q4 and full year 2025 results on March 5, 2026 with a conference call at 8:30 a.m. ET. According to Altimmune, management will discuss financial results and provide a business update during the call.

How can investors access the Altimmune (ALT) March 5, 2026 webcast and register for the conference call?

Investors can access the live webcast via Altimmune’s Investor Relations website and register for dial-in numbers. According to Altimmune, registration provides dial-in details and a unique PIN to join the March 5 conference call.

Will Altimmune (ALT) provide a replay of the March 5, 2026 earnings call and for how long?

Yes. According to Altimmune, a replay of the March 5 call will be available on the Investor Relations website for up to three months. The replay will appear shortly after the live webcast concludes for on-demand listening.

What topics will Altimmune (ALT) management cover during the March 5, 2026 business update?

Management will discuss fourth quarter and full year 2025 financial results and provide a business update on development programs. According to Altimmune, the call will cover company financials and progress on pemvidutide development for liver diseases.

What time and where should shareholders go to listen to Altimmune (ALT)’s March 5, 2026 investor call?

Shareholders should go to Altimmune’s Investor Relations website at 8:30 a.m. ET on March 5, 2026 to listen to the live webcast. According to Altimmune, the site hosts the webcast and registration links for dial-in access.